Published in:
01-03-2017 | Original Article
GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signaling
Authors:
Corinna Koch, Bardia Samareh, Tatsuya Morishima, Perihan Mir, Lothar Kanz, Cornelia Zeidler, Julia Skokowa, Karl Welte
Published in:
Annals of Hematology
|
Issue 3/2017
Login to get access
Abstract
Severe congenital neutropenia (CN) is a bone marrow failure syndrome characterized by an absolute neutrophil count (ANC) below 500 cells/μL and recurrent, life-threatening bacterial infections. Treatment with granulocyte colony-stimulating factor (G-CSF) increases the ANC in the majority of CN patients. In contrary, granulocyte-monocyte colony-stimulating factor (GM-CSF) fails to increase neutrophil numbers in CN patients in vitro and in vivo, suggesting specific defects in signaling pathways downstream of GM-CSF receptor. Recently, we detected that G-CSF induces granulopoiesis in CN patients by hyperactivation of nicotinamide phosphoribosyl transferase (NAMPT)/Sirtuin 1 signaling in myeloid cells. Here, we demonstrated that, in contrast to G-CSF, GM-CSF failed to induce NAMPT-dependent granulopoiesis in CN patients. We further identified NAMPT signaling as an essential downstream effector of the GM-CSF pathway in myelopoiesis.